Eli Lilly’s investigational obesity drug reduced phase 2 study participants’ weight by 24.2 percent after nearly a year’s worth of treatment, marking more significant weight loss results compared to other drugs currently being studied or on the market.
Read the full post on Becker's Hospital Review - Healthcare News
